Radiopharmacy |
![]() |
![]() |
![]() |
The Radiopharmacy activities are focused on the development and evaluation of radioactive drugs – “radiopharmaceuticals” – for molecular imaging and radionuclide therapy of localized and multi-focal disease, such as primary and metastatic cancer. For this purpose, suitably modified molecular beacons (e.g. antibodies, peptides, small organic molecules, or, quite recently, multi-modal delivery platforms like nanoparticles, or dextran-based polymers) are employed as carriers of diagnostic and therapeutic radiometals to disease-associated targets (like antigens, hormone receptors or transporter molecules) with a high specificity. An integer part of this effort is dedicated in the study of (radio)metal-chelator complexes, which are the “building-blocks” utilized in the derivatization of biological vectors of interest.
|